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Introduction
Obesity affects nearly 13% of the global adult population, which has led to a high prevalence of cardiometabolic complications, such as type 2 diabetes mellitus (T2DM) [1] . In China, adults who are 35 to 74 years, overweight and obese comprise approximately 3.32 million T2DM patients [2] . It is likely not possible to use a single agent to control glycemia and body weight; however, treatment with two or more agonists or single co-agonists is considered as a reasonable strategy for treating obesity and T2DM [3] . Compared with these combinatorial therapies and traditional therapies such as dietary modulation and conventional drug usage, which are correlated with poor long-term outcomes, laparoscopic bariatric surgery is much more efficient in losing weight [4] . Laparoscopic Roux-en-Y gastric bypass (LRYGB), which is a type of laparoscopic bariatric surgery, has been shown to be effective in the treatment of obstructive sleep apnea in obese T2DM patients [5] . LRYGB and laparoscopic sleeve gastrectomy (LSG) can result in significant weight loss [6] .
Recently, as dynamic modifiers, miRNAs have been shown to be involved in the pathogenesis of various conditions such as obesity and T2DM [7] . Moreover, it has been demonstrated that miR-152, miR-17, miR-138 and miR-593, which are potential biomarkers, can differentiate patients with obesity from patients with T2DM or obesity (OB) + T2DM and healthy subjects [8] . SIRT1, which is a nicotinamide adenine dinucleotide (NAD+)-dependent protein deacetylase expressed by hypothalamic neurons, functions as an attractive molecular target for the treatment of obese T2DM in hypothalamic POMC and SF1 neurons [9] . Human SIRT1 is suggested to be participated in tumorgenesis, which is mostly because of its modulating effect on p53 by the deacetylation of lysine382, and blocking the SIRT1 might results in the activation of the p53 pathway [10, 11] . The function of SIRT1 is associated with cellular metabolism, and it could sense changes of energy in the cytoplasm, nucleus, and mitochondrion through its ability [12] . In addition, SIRT1 could control the cellular responses through regulating the expression and activity of the FOXO3a and FOXO4, which is important molecules in regulating the functions of vascular smooth muscle cells (VSMCs) [13] . As miR-448 is a member of the miRNA family, we speculated that miR-448 and its target gene SIRT1 may function as potential biomarkers for obesity and T2DM. Circulating endothelial progenitor cells (EPCs) are involved in the neovascularization and maintenance of vascular homeostasis, and when dysregulated, they can play important roles in the pathogenesis of diabetic vasculopathy [14] . The majority of cells documented in T2DM are products of endothelial cell sloughing, and rather, they do not represent an increase in progenitor cells [15] . A previous study demonstrated that adverse metabolic stress factors in type 1 diabetes are associated with reduced EPC numbers and angiogenicity [16] . Thus, in this study, we selected EPCs for use in our experiments. We hypothesized that miR-448 and SIRT1 are potential critical factors that can predict surgery efficacy in obese T2DM patients. This study aimed to investigate the value of peripheral blood miR-448 and its target gene SIRT1 in predicting the treatment efficacy of laparoscopic bariatric surgery in obese T2DM patients.
Materials and Methods

Ethics statement
This study was approved by the Ethical Committee of the Second Hospital of Anhui Medical University. All patients signed an informed consent form.
Study subjects
From May 2013 to May 2015, 124 patients were diagnosed with obese T2DM in the Second Hospital of Anhui Medical University, according to the World Health Organization (WHO) diagnostic criteria (1999) for diabetes. There were 78 females and 46 males aged 25 -66 years, with a mean age of 46 years. All patients were newly diagnosed and had not received any therapy such as dietary modulation, exercise or
Enzyme-linked immunosorbent assay (ELISA)
SIRT1 protein expression in the serum was determined by ELISA kits (YY (bio)-elisa-00435, Shanghai Y-Y chemical reagents Co., Ltd, Shanghai, China). The known antibody was diluted with a packet buffer to 1 -10 μg/ml, and then 0.1 mL was added to each well and kept at 4°C overnight. The next day, the wells were washed three times for 5 min each time. The reaction well was incubated with 0.1 mL diluted supernatant for 1 h at 37°C and then washed. The reaction wells for blank, positive control and negative control (NC) were incubated with 0.1 mL diluted secondary antibody, which contained ELISA reagents (1: 1000, Wuhan Boster Bioengineering Co., Ltd., Wuhan, China), for 35 -60 min at 37°C and washed. The ddH 2 O (PER018-1, Beijing Dingguo Changsheng Biotechnology Co., Ltd., Beijing, China) was used to wash for the last time. The tetramethylbenzidine (TMB) (0.1 mL, EL0001, Huzhou InnoReagents Co., Ltd., Zhejiang, China) substrate was added to each well and incubated for 10 -30 min 37°C, 50 μl stop buffer was introduced. A microplate reader (Bio-Rad, Hercules, CA, USA) was used to calculate the optical density (OD) of each well at 450 nm within 20 min.
Efficacy evaluation
The laparoscopic bariatric surgery was considered effective if the obese T2DM patient met the following criteria: (1) clinical complete remission (cure): the patient did not require treatment via alimentary control, oral drugs or insulin after surgery. In addition, patients with random BG < 11.1 mmol/l, FBG < 7.0 mmol/l, 2-h BG < 11.1 mmol/l and HbAlc < 6.5% were considered as clinical complete remission; (2) partial clinical remission (markedly effective), the patients' FBG and HbAlc levels were controlled at normal levels after surgery with administration of hypoglycemic agents, or patients who declined hypoglycemic agents had lower FBG and HbAlc levels than before surgery but still higher levels than normal (induced FG ≥ 1.39 mmol/l, induced HbAlc ≥ 1%); (3) ineffective: with the use of hypoglycemic agents, the FBG and HbAlc levels of the patients were not markedly different after surgery compared to before surgery. Effectiveness was considered as both clinical complete remission and partial clinical remission. The time of efficacy evaluation was 3 months after surgery.
Isolation, culture and identification of EPCs
A density gradient centrifugation assay was used to obtain EPCs of obese T2DM patients. EPCs were resuspended in 5 mL M199 medium (HyClone, Logan, Ut, USA) contained 20% fetal bovine serum (FBS), 12 ng/mL VEGF, 4 ng/mL BFGF4, 100 U/mL penicillin, and 100 U/mL streptomycin, added to a culture flask coated with rat tail collagen [18] and stored at -20°C under aseptic conditions. After 4 d of culture, the liquid in the culture flask was replaced and continuously changed thereafter every day through the 7 th day, at which time adherent cells were collected for experiments. EPCs were incubated with Dil-acLDL (Sigma, Saint Louis, MO, USA) and FITC-UEA-1 (Sigma, USA) and evaluated using a confocal laser scanning microscope (CLSM). Surface antigen markers of EPCs were detected by flow cytometry. CellQuest software was used to analyze 10, 000 cells of each sample and the rates of CD34, CD133 and KDR positive expression.
EPC treatment and grouping
After identification, EPCs were grouped into blank (no transfection with any sequence), NC (transfected with the NC sequence), miR-448 mimic (transfected with the miR-448 mimic sequence), miR-448 inhibitor (transfected with the miR-448 inhibitor sequence), siRNA-SIRT1 (transfected with the siRNA-SIRT1 sequence) and miR-448 inhibitor + siRNA-SIRT1 (transfected with the miR-448 inhibitor sequence and the siRNA-SIRT1 sequence) groups. The cells were seeded in a 50-mL culture flask until the cell density reached 30 -50%. Lipofectamine 2000 (5 μL) (Invitrogen, Carlsbad, CA, USA) mixed with 100 μL serum-free medium was added to a sterile EP tube for 5 min at room temperature. SIRT1 siRNA (50 nmol) + 100 μL serum-free medium were added and kept for 20 min at room temperature to allow the DNA and Lipofectamine to become a complex, and then cells in the culture flask were washed with serum-free medium. The complex was mixed gently with serum-free medium without antibiotics and then transferred to a 50-mL culture flask without transfection. The sample was then incubated in 5% CO 2 at 37°C for 6 -8 h, and the liquid was replaced with complete medium. The cells were collected after 24 ~ 48 h of culture. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) was used to measure miR-448 expression and SIRT1 and VEGF mRNA expression, and ELISA was used to determine SIRT1 and VEGF protein expression in the supernatant.
Bioinformatics prediction software and dual-luciferase reporter gene assay
The target gene of miR-448 was analyzed by MicroRNA.org to verify whether IRT1 was the direct target gene of miR-448. To confirm the interactions between miR-448 and SIRT1, a dual-luciferase reporter gene assay was performed. Mutated sequences corresponding to the putative miR-448 binding sites were synthesized on wild-type SIRT1 and ligated into the pmiR-Report vector between SpeI and HindIII sites using T4 DNA ligase. Wild-type (WT) and mutant (Mut) were respectively co-transfected with miR-448 in HEK-239T cells. After 48 h, cells were collected and lysed. A Luciferase Assay Kit was used to detect luciferase activity.
RT-qPCR
Total RNA was extracted using a high pure RNA kit (D203-01, GenStar Biosolutions, Beijing, China). Primers specific to miR-448, SIRT1, VEGF, U6 and GAPDH were designed and synthesized by Takara Corporation (Dalian, China) ( 2 O. U6 and GAPDH were used as internal references for miR-448 and SIRT1, respectively. The differences in target gene expression between the control group and the experimental group were determined using the 2 -ΔΔCt method as follows: ΔΔCT = ΔCt experimental group -ΔCt control group ; ΔCt ＝ Ct target gene -Ct internal control , where Ct refers to the amplification cycle in the logarithmic growth phase before the real-time fluorescence intensity reached the defined threshold. Each experiment was repeated three times. The expression of mRNA was evaluated after transfection for 48 h using the methods mentioned above.
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assay
Cells in the logarithmic growth phase were used for experiments. The cell suspension was transferred in a centrifuge tube after uniformly blowing using sterile pipettes, and the number of cells was counted via trypan blue staining. The cells were seeded in a 96-well plate with 1 × 10 4 cells per well (volume of each well is 180 µL) and then cultured in an incubator with 5% CO 2 at 37°C for 0 h, 24 h, 48 h and 72 h. Then, 5% MTT solution was added to each well devoid of light and cultured in an incubator at 5% CO 2 at 37°C for 4 h continuously. Next, the cells were centrifuged at 1000 r/min for 10 min. The supernatant was removed; each well was supplemented with 100 µL dimethyl sulfoxide (DMSO) and gently mixed for 10 min to fully dissolve the formazan crystals produced by living cells. After 15 min, the 96-well plate was removed, and the absorbance at 570 nm was detected using a microplate reader (SAF-680T, Multiskan GO, Thermo, USA). Each experiment was conducted in triplicate to draw the cell survival curve with time as the abscissa axis and OD value as the longitudinal axis.
Transwell assay
The cells were digested to prepare a cell suspension and then counted, added to serum-free EBM-2 medium, and adjusted to a cell suspension of 2 × 10 5 cells/ml concentration. EBM-2 medium with 50 µg VEGF was then added to the wells, and the plate was placed in a 37°C incubator with 5% CO 2 for 60 min. Cell suspension (100 µL) was added to each transwell chamber. After incubating at 37°C and 5% CO 2 for 24 h, cells on the upper surface of the transwell chamber were removed. The cells were washed once with PBS, fixed with methanol for 15 min, stained with 4',6-diamidino-2-phenylindole (DAPI) for 30 min, and then washed again. Images were acquired with an inverted fluorescence microscope. The cells that had transferred to the bottom chamber were counted in five selected fields (× 100) in each well and analyzed.
Adherence test
After 2 min of digestion with 0.25% trypsin, the cell reaction was stopped with cell culture medium, and the cell culture medium was transferred to a plate using a straw. Cell suspension was obtained after the adherent cells in the plate were removed from the wall. The cell suspension was centrifuged (at room temperature) at 200 r/min for 6 min in a 15-mL centrifuge tube. After removing the supernatant, cells were counted, mixed and seeded into a culture plate packed with HFN and then incubated in a 5% CO 2 incubator at 37°C. Adherent cells were counted after 30 min.
Tube formation assay
Transfected cells were resuspended with EBM-2 basal medium containing with 2% FBS. Then, 5 × 10 4 cells were added to each well of a 48-well plate pre-treated with Matrigel-Matrix. When the cells adhered to the wall, cells were cultured in serum-free medium for 72 h. The number of tubular structures was assessed using an inverted microscope (40 ×). The cells were counted in six fields of views to obtain the mean value.
Statistical analysis SPSS 21.0 software (IBM Corp. Armonk, NY, USA) was applied for statistical analyses. Categorical data were presented as ratios or percentages. Chi-square test was used for comparisons between groups. Measurement data were expressed as the mean ± standard deviation (SD). Differences between two groups were compared by t tests. One-way analysis of variance (ANOVA) was employed for comparisons among multiple groups. Receiver operating characteristic (ROC) curves were used to evaluate the utility of miR-448 and SIRT1 for predicting the efficacy of surgery in obese T2DM patients. Pearson's correlation analysis was used to evaluate the correlation between miR-488 and SIRT1. Two-sided tests were used for all statistical tests, and P < 0.05 was considered significantly different.
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Results
Preoperative and postoperative clinicopathological characteristics of obese T2DM patients
The clinicopathological characteristics of patients before and after laparoscopic bariatric surgery are shown in Table 2 . Body mass index (BMI), FBG, 2-h BG, FINS, HbAlc and HOMA-IR decreased (all P < 0.05), whereas HOMA-β and HOMA-IS increased after surgery compared to before surgery (all P < 0.05). There was no significant difference in the preoperative clinicopathological characteristics between the effective and ineffective groups (all P > 0.05). After surgery, BMI, FBG, 2-h BG, FINS, HbAlc and HOMA-IR were decreased, while HOMA-β and HOMA-IS were increased in the effective group compared with the ineffective group (all P < 0.05).
Expression levels of miR-448 and SIRT1 mRNA before and after surgery
As shown by the RT-qPCR results presented in Fig. 1A , compared with before surgery, the expression of miR-448 in the peripheral blood significantly decreased and the mRNA expression of SIRT1 was prominently enhanced after surgery (all P < 0.05). Compared with the pre-surgery values, the levels of miR-448 and SIRT1 mRNA in the peripheral blood were not significantly different after surgery in the ineffective group; for patients in the effective group, the expression of miR-448 in the peripheral blood was significantly lower after surgery than before surgery, while the expression of SIRT1 mRNA was significantly higher (Fig. 1B~C) .
The results of Pearson's correlation analysis showed that the expression of SIRT1 mRNA was significantly reduced with an increase in miR-488 expression; therefore, the two molecules were negatively correlated (r = -0.398, P < 0.001) (Fig.  1D ).
Protein expression of SIRT1 was upregulated in the effective group after surgery As shown in Fig. 2A , the preoperative and postoperative protein levels by ELISA of SIRT1 were 7.76 ± 3.27 and 9.83 ± 4.14, respectively. The protein expression of SIRT1 in the serum was significantly higher after post-surgery than pre-surgery (P < 0.05). As shown in Fig. 2B , the protein expression of SIRT1 in the serum of patients in the effective group was significantly higher postsurgery than pre-surgery (P < 0.05), whereas it was not significant altered after surgery in the ineffective group (P > 0.05).
ROC curve analysis for evaluating the value of miR-448 and SIRT1 as predictors of surgery efficacy in obese T2DM patients
The areas under the ROC curves (AUCs) for miR-448 and SIRT1 expression were 0.893 (95% CI: 0.815~0.971) and 0.730 (95% CI: 0.626~0.834), respectively. At the optimal cutoff value, that relative expression levels of miR-448 and SIRT1 in the plasma were 1.615 and 1.415, respectively, and the specificities of miR-448 and SIRT1 for the prediction of laparoscopic bariatric surgery efficacy in obese T2DM patients were 92.70% and 82.00%, respectively, with sensitivities of 82.10% and 40.40%, respectively (Fig. 3A~B) .
Correlation of miR-448 and SIRT1 mRNA levels with the clinicopathological characteristics of obese T2DM patients before and after surgery There was no difference between the miR-448 and SIRT1 high expression group and the miR-448 and SIRT1 low expression group before and after surgery (all P > 0.05). Compared with before surgery, BMI, FBG, 2-h BG, FINS, HbAlc and HOMA-IR were significantly reduced, while HOMA-β and HOMA-IS were enhanced in the effective group after surgery (all P < 0.05). After treatment, BMI, FBG, 2-h BG, FINS, HbAlc, and HOMA-IR were clearly decreased but HOMA-β and HOMA-IS were increased in patients with low miR-448 expression relative patients; miR-448, microRNA-448; T2DM, type 2 diabetes mellitus; ROC, receiver operating characteristics; T2DM, type 2 diabetes mellitus. Fig. 3 . ROC curve analysis of miR-448 and SIRT1 expression as predictors of surgery efficacy in obese T2DM patients. Note: A, ROC curve of miR-448 expression as a predictor of surgery efficacy in obese T2DM patients; B, ROC curve of SIRT1 expression as a predictor of surgery efficacy in obese T2DM patients; miR-448, microRNA-448; T2DM, type 2 diabetes mellitus; ROC, receiver operating characteristics; T2DM, type 2 diabetes mellitus.
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to patients with high miR-448 expression (all P < 0.05). Moreover, BMI, FBG, 2-h BG, FINS, HbAlc, and HOMA-IR were higher but HOMA-β and HOMA-IS were lower in patients with high SIRT1 expression than in patients with low SIRT1 expression (all P < 0.05) ( Table 3 and  Table 4 ).
Low expression of miR-448 and high expression of SIRT1 indicate favorable efficacy of laparoscopic bariatric surgery in obese T2DM patients
Based on the ROC curves corresponding to miR-448 and SIRT1 levels in the peripheral blood, as shown in Fig. 3 , the cutoff values for the relative expression levels of miR-448 and SIRT1 were 1.615 and 1.415, respectively. Thus, patients with a miR-448 expression greater than 1.615 were classified into the miR-448 high expression group, and vice versa. Similarly, patients with SIRT1 expression greater than 21.415 were classified into the SIRT1 high expression group, and vice versa. Treatment efficacy between the groups is shown in Table 5 . The cure rates of the miR-448 low and high expression groups were 77.17% and 18.75%, respectively, while the cure rates of the SIRT1 low and high expression groups were 38.10% (Table 6 ).
SIRT1 is a target gene of miR-448
The biology website microRNA.org indicates that miR-448 can directly target SIRT1 (Fig. 4A) . To confirm that SIRT1 is a direct target gene of miR-448, luciferase reporter plasmids SIRT1-Wt and SIRT1-Mut harboring the 3'-UTR of SIRT1 mRNA were constructed. The results were compared with the NC group (P < 0.05) (Fig. 4B) , while the mutant SIRT1 mut-3'-UTR was not decreased in both groups (P > 0.05). Thus, SIRT1 is a target gene of miR-448 and can be negatively regulated by miR-448.
Identification of EPCs
As shown in Fig. 5A , cells were identified by CLSM after mononuclear cells were cultured for 7 d. The cells absorbed Dil-acLDL (red, excitation wavelength of 543 nm) and (Fig. 5B) , further confirming that the cells were EPCs.)
miR-448 and si-SIRT1 inhibited cell viability of EPCs
The results of the MTT assay are shown in Fig.  6 , there were dramatical differences in each group at 24 h, 48 h and 72 h compared to 0 h (all P < 0.05). Compared with the blank and NC groups, the cell viability of EPCs was reduced in the miR-448 mimic and si-SIRT1 groups but elevated in the miR-448 inhibitor group (all P < 0.05). EPC viability did not differ between the blank group and the NC group or the miR-448 inhibitor + si-SIRT1 group (P > 0.05). This experiment revealed that miR-448 and si-SIRT1 inhibited cell viability of EPCs. 4 . Verification of the targeting relationship between miR-448 and SIRT1 using bioinformatics prediction software and luciferase reporter gene assay. Note: A, Predicted binding site of miR-448 on SIRT1 on the SIRT1 3'UTR; B, Results of the dual luciferase reporter assay show that miR-448 regulates the expression of SIRT1; *, compared with the NC group, P<0.05; miR-448, microR-NA-448; NC, negative control; SIRT1-wt, SIRT1 wild type; SIRT1-mut, SIRT1 mutant. 
miR-448 and si-SIRT1 can prevent EPC migration
The result of EPC migration based on the transwell assay is shown in Fig.  7 . Cell migration ability was lower in the miR-448 mimic and si-SIRT1 groups than in the blank and NC groups, while it was higher in the miR-448 inhibitor group (all P < 0.05). EPC migration did not differ between the blank group and the NC group or the miR-448 inhibitor + si-SIRT1 group (P > 0.05). This result showed that miR-448 and si-SIRT1 can prevent EPC migration.
miR-448 and si-SIRT1 may repress cell adhesion of EPCs
According to the results of the adherence test (Fig. 8) , the numbers of adherent cells in the blank, NC and miR-448 inhibitor + si-SIRT1 groups were 589 ± 25, 577 ± 14 and 596 ± 20, respectively. Cell adhesion showed no significant difference among the blank, NC and miR-448 inhibitor + si-SIRT1 groups (all P > 0.05). The number of adherent cells in the miR-448 mimic and si-SIRT1 groups was 389 ± 25 and 410 ± 16, which were markedly less than the number in the blank and NC groups. The miR-448 inhibitor group exhibited more adherent cells (650 ± 16) than the blank and NC groups (all P < 0.05). These results indicated that miR-448 and si-SIRT1 may repress cell adhesion of EPCs.
miR-448 and si-SIRT1 restrained angiogenesis of EPCs
The degrees of tube formation in the blank, NC, miR-448 mimic, miR-448 inhibitor, si-SIRT1 and miR-448 inhibitor + si-SIRT1 groups were 5.67 ± 0.58, 5.33 ± 0.58, 2.33 ± 0.58, 9.67 ± 0.58, 2.00 ± 1.10 and 6.33 ± 0.58, respectively, according to the tube formation assay (Fig. 9 ). There were no differences among the blank, NC and miR-448 inhibitor + si-SIRT1 groups (all P > 0.05). Compared with the blank and NC groups, angiogenesis of EPCs was decreased in the miR-448 mimic and si-SIRT1 groups, while increased in the miR-448 inhibitor group (all P < 0.05). The above findings suggest that miR-448 and si-SIRT1 can restrain angiogenesis of EPCs.
miR-448 affects angiogenesis of EPCs by regulating VEGF
As shown in Fig. 10A , the expression of miR-448 did not differ between the blank group and the NC group or the si-SIRT1 group (all P > 0.05). Compared to the blank and NC groups, the expression of miR-448 was upregulated in the miR-448 mimic group and downregulated in the miR-448 inhibitor and miR-448 inhibitor + si-SIRT1 group (all P < 0.05). As shown in Fig. 10B , SIRT1 and VEGF were expressed less frequently in the miR-448 mimic and si-SIRT1 groups, while SIRT1 and VEGF were expressed more frequently in the miR-448 inhibitor group than in the blank and NC groups. Together, these findings revealed that miR-448 affects angiogenesis of EPCs by regulating VEGF.
Discussion
With the increasing prevalence of T2MD worldwide, it is becoming increasingly important to fully understand the risk factors for diabetic complications [19] . Traditional methods such as dietary modulation and conventional drugs for managing T2DM have unsatisfactory long-term efficacy [20] . However, bariatric surgery has been proven to have high efficacy in the treatment of diabetes and is used for patients whose disease severity cannot be controlled by behavioral, dietary, nutritional adjustments and pharmaceutical compounds [21] . After laparoscopic bariatric surgery, patients experience weight loss together with improvements in metabolic syndromes [22, 23] . Thus, this study aimed to determine the role of miR-448 in targeting SIRT1, thus affecting the efficacy of laparoscopic bariatric surgery for the treatment of obese T2DM patients. In addition, we found that miR-448 may reduce the efficacy of laparoscopic bariatric surgery in obese T2DM patients by downregulating SIRT1. 
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Recent animal and clinical studies have indicated that decreased numbers and poor function of EPCs not only increases cardiovascular risk but also contributes to impaired heart and vessel repair in DM patients [19, 24] . Dysfunction of EPCs is the primary cause of oxidative damage, and the nitric oxide (NO) system is mainly responsible for oxidative stress in T2DM patients [25] . Thus, our study utilized EPCs from obese T2DM patients, and we found that miR-448 and si-SIRT1 could repress the migration, adhesion and angiogenesis of EPCs in vivo. SIRT1 plays a core role in the biological properties of EPCs. SIRT1 regulates the PI3K/Akt/eNOS signaling pathway to promote the migration of EPCs [26] . SIRT1, as a critical modulator, leads to EPC dysfunction during alterations in glucose metabolism [27] . Poor glycemic control in T2DM patients influences SIRT1 signaling via platelet-activating factor receptor activation to reduce the number of EPCs [28] . To date, numerous miRs have been found to have implications in cardiovascular pathology and have the potential to contribute to EPC repair [29] . Our study demonstrated that SIRT1 is a target gene of miR-488 and can be negatively regulated by miR-448. All the above evidence supports our results.
In addition, we found that miR-448 was expressed at high levels and SIRT1 was expressed at low levels in the peripheral blood of obese T2DM patients. Similarly, the expression of miR-448 is elevated in gastric cancer and oral squamous cell carcinoma [30, 31] . It has been shown that the increased expression of SIRT1 can enhance insulin sensitivity; moreover, SIRT1 is expressed less frequently in insulin-resistant cells, suggesting that the low expression of SIRT1 before surgery is indicative of cellular resistance to insulin [32] . Additionally, SIRT1 is known as a main factor that involved in adaptive response against oxidative stress (OS) and also the improvement of energy efficiency, as well as allowing the cells to adapt to the status of energy stress [33] . It has been reported that Evidence have shown that as a natural polyphenol in red wine and grapes, resveratrol can activate the SIRT1 and increase insulin sensitivity except for its effects on mitochondrial energetics [34] . Resveratrol could communicate with insulin signaling through its downstream pathways, such as eNOS and SIRT1 [35] . Furthermore, we found that low expression of miR-448 or high expression of SIRT1 may enhance surgery efficacy in obese T2DM patients. Using bioinformatics prediction software and a dual-luciferase gene reporter assay, we showed that miR-448 could target SIRT1 mRNA and suppress its expression.
Furthermore, miR-448 expression was negatively correlated with surgery efficacy in obese T2DM patients, whereas SIRT1 expression was positively correlated with surgery efficacy in obese T2DM patients. In colorectal cancer cells, insulin-like growth factor 1 receptor (IGF1R) was identified as a target gene of miR-448 [36] . Sherajee et al. also demonstrated that IGF1R affects insulin signaling [37] , and furthermore, it has already been shown that miR-448 might affect insulin sensitivity by regulating IGF1R. Additionally, adriamycin-activated nuclear factor-κB (NF-κΒ) was demonstrated to directly bind to the miR-448 promoter [38] . In T2DM, feed-forward signaling of tumor necrosis factor-α (TNF-α) and NF-κΒ through the IKK-Β pathway has been shown to decrease insulin sensitivity and cause coronary arteriolar dysfunction [39] . Wang et al. showed that inhibition of IKKβ/NF-κΒ signaling can alleviate insulin resistance [40] . Therefore, we suggest that miR-448 might affect surgery efficacy in obese T2DM patients through a mechanism that may be partially related to the NF-κΒ signaling pathway. Moreover, Milne et al. demonstrated that SIRT1 activators enhance insulin sensitivity and whole-body glucose homeostasis, indicating that SIRT1 activation might be a potential therapeutic strategy for the treatment of T2DM [41] . In addition, SIRT1 may affect insulin secretion by regulating UCP2 in β-cells [42] . As a crucial activator of SIRT1, SRT1720 can improve insulin sensitivity and glucose tolerance to protect against diet-induced obesity; thus, the positive therapeutic efficacy of SIRT1 might be related to its activators, such as SRT1720 [43] . According to Gerhart-Hines et al., SIRT1 acts as a regulator of PGC-1a, which enhances transcription programs by regulating the expression of metabolic genes involved in mitochondrial fatty acid oxidation [44] . In addition to the relative level of miR-448, FBG, 2-h BG and HOMA-IR are predictive of unfavorable surgery efficacy. Similarly, Inoue et al. demonstrated that FBG is a predictive factor for T2DM [45] . Postprandial BG level is also considered to be indicative of diabetes [46, 47] . Cho et al. also showed that HOMA-IR is a marker of diabetes onset [48] . Considering all of the above information, miR-448 and its target gene SIRT1 might be potential biomarkers for predicting the efficacy of laparoscopic bariatric surgery in obese T2DM patients. Our results indicated that miR-448 and SIRT1 could be therapeutic targets for obesity accompanied with T2DM. However, this study was primarily focused on the interactions between miR-448 and SIRT1, and we compared the effects of the two factors on clinical surgical treatment efficacy. Thus, further mechanistic studies need to be carried out in the future. However, the accuracy of our interpretations may be influenced by the sample size and duration of data collection, and the experimental design could be further improved with regard to data collection and analysis. In the future, we plan to investigate the mechanisms by which miR-448 and SIRT1 affect treatment outcomes in obese T2DM patients who undergo laparoscopic bariatric surgery.
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